| rivaroxaban / Generic mfg. |
ChiCTR1800016878: An Open-label, randomised, single dose, two-way,four cycles bioequivalence study to compare the bioequivalence of oral rivaroxaban tablets in Chinese healthy volunteers under fasting/fed conditions |
|
|
| Recruiting | 1 | 60 | | TRTR ;RTRT ;TRTR ;RTRT | Beijing Shijitan Hospital Capital Medical University; BEIJING SL PHARM, BEIJING SL PHARM | antithrombotic | | | | |
2019-001759-38: Uptake, Distribution and Elimination of the drugs rivaroxaban, apixaban and edoxaban given together in small doses to children with simple heart defects. |
|
|
| Not yet recruiting | 1 | 20 | Europe | Edoxaban-Konzentrag zut Herstellung einer Lösung zum Einnehmen, Apixaban-Konzentrat zur Herstellung einer Lösung zum Einnehmen, Rivaroxaban-Konzentrat zur Herstellung einer Lösung zum Einnehmen, Concentrate for oral solution, Solution for injection, Tablet, Dormicum® V 5 mg/5 ml, Yohimbinum hydrochloricum D4 | Ruprecht-Karls University Heidelberg Medical Faculty, University Hospital represented in law by its commercial director, University of Heidelberg | 20 children with non-cyanotic congenital heart defects especially atrial septal defects (ASD) and ventricular septal defects (VSD) in admitted to the paediatric cardiology wards will be included. These children undergo a cardiac surgery prior to the study participation. 20 Kinder mit angeborenen nicht zyanotischen Herzfehlern, im speziellen Atrium Septum Defekte (ASD) und Ventrikel Septum Defekte (VSD), welche als Patienten auf der kinderkardiologischen Station sind. Diese Kinder bekommen vor der Studienteilnahme einen herzchirurgischen Eingriff., Children with congenital heart diseases. This heart disease need a surgical Treatment. Die Kinder haben einen angeborenen Herzfehler, welcher chirurgisch behandelt werden muss., Body processes [G] - Metabolic Phenomena [G03] | | | | |
ChiCTR1900025249: A Phase I, Multiple Ascending Dose, Single-center Study to Assess the Tolerability and Pharmacokinetic of ZIFA01 in Chinese Healthy Subjects |
|
|
| Not yet recruiting | 1 | 53 | | 5 mg ZIFA01/Placebo /rivaroxaban ;10 mg ZIFA01/Placebo /20mg rivaroxaban ;15 mg ZIFA01/Placebo /20mg rivaroxaban ;7.5 mg ZIFA01/Placebo | Peking University First Hospital; Tianjin Pharmaceutical Research Institute Co., Ltd., Bidding unit | Thrombotic disease | | | | |
NCT04729998: Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions |
|
|
| Not yet recruiting | 1 | 34 | RoW | Rivaroxaban film-coated tablet 20 mg, The test product, Xarelto® film-coated tablet 20 mg, The reference product | Pharmtechnology LLC, ClinPharmInvest, LLC | Bioequivalence | 02/21 | 02/21 | | |
NCT04753489: Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions |
|
|
| Not yet recruiting | 1 | 34 | RoW | Rivaroxaban film-coated tablet 10 mg, The test product, Xarelto® film-coated tablet 10 mg, The reference product | Pharmtechnology LLC, ClinPharmInvest, LLC | Bioequivalence | 03/21 | 03/21 | | |
| Not yet recruiting | 1 | 56 | | Administration under fasting condition (TRTR) ;Administration under fed condition (TRTR) ;Administration under fasting condition (RTRT) ;Administration under fed condition (RTRT) | Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University; The Third Xiangya Hospital, Central South University, Nanjing Hencer Pharmaceutical. Co.,Ltd | Thromboembolism disease | | | | |
ChiCTR2300074874: The bioequivalence test of rivaroxaban tablets in healthy subjects under the conditions of random, open, two preparations, single administration, four cycle repeated cross fasting and postprandial status |
|
|
| Completed | 1 | 72 | | Subjects took the test preparation in the first cycle, took the reference preparation in the second cycles, took the test preparation in the third cycle, took the reference preparation in the forth cycles. ;Subjects took the reference preparation in the first cycle, took the test preparation in the second cycles, took the reference preparation in the third cycle, took the test preparation in the forth cycles. ;In the postprandial state, the subjects took the test preparation in the first cycle, took the reference preparation in the second cycles, took the test preparation in the third cycle, took the reference preparation in the forth cycles. ;In the postprandial state, the subjects took the reference preparation in the first cycle, took the test preparation in the second cycles, took the reference preparation in the third cycle, took the test preparation in the forth cycles. | Huzhou Central Hospital, Zhejiang Province; Suzhou Dongrui Pharmaceutical Co., Ltd, Suzhou Dongrui Pharmaceutical Co., Ltd | Anticoagulant treatment | | | | |
NCT04874428: Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis |
|
|
| Recruiting | 1 | 24 | Europe | Rivaroxaban 10 mg Oral Tablet, Xarelto, Apixaban 2.5 mg Oral Tablet, Eliquis | University Hospital Inselspital, Berne, Centre Hospitalier Universitaire Vaudois | Liver Cirrhosis | 12/21 | 12/21 | | |
CLOTRx, NCT03864406: Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers |
|
|
| Completed | 1 | 12 | US | Cobicistat, Tybost, Darunavir/Cobicistat, Prezcobix, Rivaroxaban, Xarelto | National Institutes of Health Clinical Center (CC) | Healthy Volunteers | 12/22 | 12/22 | | |
NCT04994223: Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease |
|
|
| Recruiting | 1 | 60 | RoW | Rivaroxaban 10 MG Oral Tablet [Xarelto] | Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi | Combined Anticoagulation and Antithrombotic Therapy, PAD - Peripheral Arterial Disease | 12/22 | 12/22 | | |
NCT05152420: Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects |
|
|
| Completed | 1 | 105 | Europe | VMX-C001, Placebo, Apixaban, Rivaroxaban, Edoxaban | VarmX B.V. | Coagulation Disorder | 02/23 | 02/23 | | |
NCT05308030: Outcomes of Rivaroxaban and Aspirin in PAD After Endovascular Revascularization |
|
|
| Not yet recruiting | 1 | 100 | NA | Rivaroxaban and Aspirin | Assiut University | Peripheral Arterial Disease | 05/23 | 07/23 | | |
NCT05723510: PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers |
|
|
| Completed | 1 | 87 | RoW | Tegoprazan 50mg, K-CAB Tab. 50 mg, Edoxaban 60mg, Lixiana Tab. 60mg, Apixaban 5mg, Eliquis Tab. 5 mg, Rivaroxaban 20mg, Xarelto Tab. 20 mg | HK inno.N Corporation | Healthy | 07/23 | 07/23 | | |
| Not yet recruiting | 1 | 100 | NA | New oral anticoagulant (rivaroxaban) and Marevan (warfarin) | Assiut University | Acute DVT of Lower Extremity | 04/25 | 06/25 | | |
| Active, not recruiting | 1 | 24 | Europe | Apixaban 5 MG Tab, Edoxaban, Dabigatran, rivaroxaban, Dabigatran 150 MG Tab, Apixaban, Edoxaban, Rivaroxaban, Edoxaban 60Mg Tab, Apixaban, Dabigatran, Rivaroxaban, Rivaroxaban 20 MG Tab, Apixaban, Edoxaban, Dabigatran | Doasense GmbH | Anticoagulant Therapy | 12/23 | 12/23 | | |
| Recruiting | 1 | 48 | Europe | VMX-C001, Placebo, Rivaroxaban 20 mg Oral Tablet, Apixaban 5 mg Oral Tablet, Edoxaban 60 mg Oral Tablet | VarmX B.V. | Coagulation Disorder | 09/24 | 09/24 | | |
NCT06444178: Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants |
|
|
| Not yet recruiting | 1 | 224 | NA | Aspirin, REGN9933, REGN7508, Rivaroxaban | Regeneron Pharmaceuticals | Healthy Volunteers | 04/25 | 07/25 | | |
CAT_PB, NCT06065592: Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms |
|
|
| Recruiting | 1 | 500 | RoW | Palbociclib, Ibrance, Rivaroxaban, Xarelto, SNP, Risk Allele(s) | Lebanese University, Haykel Hospital | Cancer, Solid Tumor, Thromboembolism, Cardiovascular Diseases, Immune System Diseases, Inflammatory Diseases, Colon Cancer, Breast Cancer, Prostate Cancer, Hepatocellular Carcinoma, Lung Cancer, Chemotherapy, Immunotherapy | 12/24 | 12/24 | | |
ChiCTR-INR-17010495: A comparative study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture |
|
|
| Recruiting | N/A | 102 | | oral Rivaroxaban ;hypodermic injection low-molecular-weight heparin ;low-molecular-weight heparin with sequential Rivaroxaban | The Second Affiliated Hospital of Xi'an Jiaotong University; The Second Affiliated Hospital of Xi'an Jiaotong University, self-collected funds | hip fracture | | | | |
ChiCTR-IPR-17011502: A Programme of Pre Study in Subjects to Assess the Bioequivalence of Rivaroxaban Tablets |
|
|
| Recruiting | N/A | 44 | | fasting delivery of test preparation Rivaroxaban Tablets (dose once,10mg) ;fed delivery of test preparation Rivaroxaban Tablets (dose once,10mg) ;fasting delivery of reference preparation Rivaroxaban Tablets (dose once,10mg) ;fed delivery of reference preparation Rivaroxaban Tablets (dose once,10mg) | The First Hosptial of Nanjing; Nanjing ChiaTai TianQing Pharmaceuticals LP, self-raised | A hip or knee replacement,Prevent venous thrombosis | | | | |
ChiCTR-ONC-17011510: Effect of rivaroxaban on preventing deep-vein thrombosis in aged diabetics with femoral neck fractures after hip replacement |
|
|
| Completed | N/A | 236 | | rivaroxaban ;Non rivaroxaban | Weifang People's Hospital; Weifang People's Hospital, Hospital funds | Deep-vein thrombosis in aged diabetics with femoral neck fractures after hip replacement | | | | |
| No Longer Available | N/A | | NA | Rivaroxaban, Xarelto 15 mg | Hospital Ana Nery, Federal University of Bahia | Prosthesis; Cardiac, Heart, Functional Disturbance as Result | | | | |
ChiCTR-INR-17013547: Administering aspirin and rivaroxaban to prevent deep venous thrombosis after total hip arthroplasty:a prospective randomised control trial |
|
|
| Not yet recruiting | N/A | 150 | | aspirin versus rivaroxaban | Department of Orthopaedic Surgery, West China Hospital, West China Medical School, Sichuan University; Department of Orthopaedic Surgery, West China Hospital, West China Medical School, Sichuan University, self-fund | deep vein thrombosis | | | | |
ChiCTR-ROC-16010005: Investigation of the intra-individual variability in exposure and pharmacological effect of rivaroxaban in joint arthroplasty patients |
|
|
| Not yet recruiting | N/A | 400 | | administered rivaroxaban 10mg,qd,po | Drum Tower Hospital Affiliated to Medical School of Nanjing University; Drum Tower Hospital Affiliated to Medical School of Nanjing University, raise (funds/etc.) independently | joint arthroplasty | | | | |
ChiCTR1800014584: Clinical efficacy of small dose aspirin in the prevention of deep venous thrombosis and pulmonary embolism after total knee arthroplasty. |
|
|
| Not yet recruiting | N/A | 120 | | Asprin ;Rivaroxaban | Department of Orthopaedics, West China Hospital, Sichuan University; West China Hospital, The balance of personal research funds. | Knee osteoartritis;Rheumatoid arthritis | | | | |
ChiCTR2000029238: The optimistic anti-coagulation regimen for patients underwent total knee arthroplasty under the background of enhanced recovery after surgery |
|
|
| Not yet recruiting | N/A | 90 | | Rivaroxaban 10mg per day after surgery ;aspirin 100mg per day after surgery ;chemotherapy sparing | Xi’an Honghui Hospital; Xi'an Honghui Hospital, self-raised | knee joint disease | | | | |
| Recruiting | N/A | 1000 | RoW | Dabigatran, rivaroxaban, apixaban, edoxaban, Direct oral anticoagulants | National Taiwan University Hospital | Ischemic Stroke, Anticoagulant Adverse Reaction | 12/25 | 12/25 | | |
| Completed | N/A | 811 | US | Rivaroxaban, Xarelto, Apixaban, Eliquis, Edoxaban, Savaysa, Dabigatran, Pradaxa, Warfarin, Coumadin, Dalteparin, Fragmin, Enoxaparin, Lovenox, Fondaparinux, Arixtra | Alliance Foundation Trials, LLC., Patient-Centered Outcomes Research Institute | Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot | 10/20 | 02/21 | | |
NCT04593056: Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data |
|
|
| Completed | N/A | 102636 | US | Warfarin, Rivaroxaban | Brigham and Women's Hospital | Atrial Fibrillation | 02/21 | 02/21 | | |
NCT06194617: Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients |
|
|
| Recruiting | N/A | 300 | RoW | Direct oral anticoagulant | Peking Union Medical College Hospital | Pulmonary Embolism, Venous Thromboembolism, Anticoagulant-induced Bleeding | 09/26 | 09/26 | | |
| Recruiting | N/A | 324 | Europe | Rivaroxaban, Acetylsalicylic acid, Clopidogrel, Edoxaban, Dabigatran, Apixaban | Rigshospitalet, Denmark, Aarhus University Hospital Skejby | Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases, Heart Valve Diseases, Valve Disease, Aortic | 01/25 | 01/29 | | |
NCT04879407: Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data |
|
|
| Completed | N/A | 98947 | US | Rivaroxaban, Warfarin | Brigham and Women's Hospital | Pulmonary Embolism | 06/21 | 06/21 | | |
ChiCTR2000033767: Therapeutic drug monitoring-guided dose adjustment of rivaroxaban in patients with nonvalvular atrial fibrillation: a randomized controlled trial. |
|
|
| Not yet recruiting | N/A | 60 | | TDM Pharmaceutical Service ;Conventional treatment | Shanghai Jiaotong University Affiliated Sixth People's Hospital; Shanghai Jiaotong University Affiliated Sixth People's Hospital, Clinical Pharmacy Innovation Research Institute of Shanghai Jiao Tong University School of Medicine | nonvalvular atrial fibrillation | | | | |
ChiCTR2300073293: The bioequivalence test of rivaroxaban tablets in subjects under fasting conditions |
|
|
| Completed | N/A | 54 | | The test preparation was taken orally in stage 1, the reference preparation was taken orally in stage 2, the test preparation was taken orally in stage 3, the reference preparation was taken orally in stage 4 ;The reference preparation was taken orally in stage 1, the test preparation was taken orally in stage 2, the reference preparation was taken orally in stage 3, the test preparation was taken orally in stage 4 | Hebei General Hospital; Tianjin Pharmaceutical Research Institute Pharmaceutical Industry Co., LTD, Tianjin Pharmaceutical Research Institute Pharmaceutical Industry Co., LTD | Bioequivalence study in healthy subjects | | | | |
ChiCTR2300073302: The bioequivalence test of rivaroxaban tablets in subjects under fed conditions |
|
|
| Completed | N/A | 28 | | The test preparation was taken orally in stage 1, the reference preparation was taken orally in stage 2, the test preparation was taken orally in stage 3, the reference preparation was taken orally in stage 4 ;The reference preparation was taken orally in stage 1, the test preparation was taken orally in stage 2, the reference preparation was taken orally in stage 3, the test preparation was taken orally in stage 4 | Hebei General Hospital; Tianjin Pharmaceutical Research Institute Pharmaceutical Industry Co., LTD., Tianjin Pharmaceutical Research Institute Pharmaceutical Industry Co., LTD. | Bioequivalence study in healthy subjects | | | | |
ChiCTR2100051588: Pilot Study to Evaluate the Pharmacokinetic of Rivaroxaban Fine Granules in Healthy Subjects |
|
|
| Recruiting | N/A | 20 | | Delivery order: RTRT ;Delivery order: TRTR | Dongyang Hengdian Hospital; Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd., Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. | Pharmacokinetic study | | | | |
| Enrolling by invitation | N/A | 416000 | US | Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days), Apixaban: extended treatment (e.g at least 90 days), Apixaban: extended treatment (e.g at least 180 days), Apixaban: extended treatment (e.g at least 270 days), Rivaroxaban: extended treatment (e.g at least 90 days), Rivaroxaban: extended treatment (e.g at least 180 days), Rivaroxaban: extended treatment (e.g at least 270 days), Edoxaban: extended treatment (e.g at least 90 days), Edoxaban: extended treatment (e.g at least 180 days), Edoxaban: extended treatment (e.g at least 270 days), Warfarin: extended treatment (e.g at least 90 days), Warfarin: extended treatment (e.g at least 180 days), Warfarin: extended treatment (e.g at least 270 days) | Brigham and Women's Hospital, Harvard Medical School (HMS and HSDM), Patient-Centered Outcomes Research Institute | Deep Venous Thrombosis, Pulmonary Embolism | 10/21 | 10/21 | | |
ChiCTR2000039907: Comparison of efficacy and safety of one-stop treatment of atrial fibrillation with rivaroxaban and warfarin and study on antithrombotic therapy after one-stop operation |
|
|
| Recruiting | N/A | 120 | | radiofrequency ablation and left atrial appendage closure ;warfarin Oral ;Levashaban oral ;oral warfarin after operative ;oral rivastaben after operative ;oral dabigatran after operative | Affiliated Hospital of Qingdao University; Affiliated Hospital of Qingdao University, Self-financing | Auricular fibrillation | | | | |
ChiCTR1900022313: A randomized controlled study for the effect of Rivaroxaban ,Warfarin,Dabigatran etexilate on the recurrence of non-valvularatrial fibrillation after catheterradio frequency ablation and mechanism exploration |
|
|
| Recruiting | N/A | 300 | | oral rivaroxaban film-coated tablet 15 or 20 mg (10 or 15 mg in specific population) qd for entire study period ;oral dabigatran etexilate capsule 110 or 150 mg (110 mg in specific population) bid for entire study period ;oral warfarin with adjusted dose due to INR level | The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine, self-financing | Atrial Fibrillation | | | | |
ChiCTR2000033729: An exploratory study of antithrombotic therapy with novel oral anticoagulants for atrial fibrillation patients with bioprosthetic valves |
|
|
| Recruiting | N/A | 200 | | rivaroxaban 20mgQd or 15mg Qd ;warfarin(INR1.8-3.0) | Fuwai Hospital, Chinese Academy of Medical Sciences; Fuwai hospital, Capital’s Funds for Health Improvement and Research | atrial fibrillation/flutter and bioprosthetic heart valves | | | | |
NCT04056143: Precision Medicine Platform for Novel Oral Anticoagulants |
|
|
| Recruiting | N/A | 500 | RoW | Pharmacogenomics, Prothrombin time (PT), activated partial thromboplastin time (aPTT), Ecarin-based assay (for dabigatran), chromogenic anti-Xa assays (for rivaroxaban, apixaban, and edoxaban) | Kaohsiung Medical University | Anticoagulant Adverse Reaction | 12/21 | 12/22 | | |
ChiCTR2200060169: Effectiveness of tranexamic acid combined with different antithrombotic agents in total knee arthroplasty |
|
|
| Completed | N/A | 180 | | Application of Rivaroxaban ;Application of Daparin sodium ;Application of aspirin | Affiliated Hospital of Qinghai University; Affiliated Hospital of Qinghai University, self-funded | N/A | | | | |
PAD_RIV_CLI, NCT04305028: Influence of Rivaroxaban for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic PAD |
|
|
| Not yet recruiting | N/A | 100 | NA | Rivaroxaban, Rivaroxaban 2.5 MG, Xarelto, Aspirin, Acetylsalicylic acid | Poznan University of Medical Sciences, Poznan University of Physical Education | Peripheral Arterial Disease | 12/21 | 12/24 | | |
NCT03792152: A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation |
|
|
| Not yet recruiting | N/A | 80 | NA | Rivaroxaban, Warfarin | The Second Affiliated Hospital of Chongqing Medical University | Atrial Fibrillation, Left Atrial Appendage Thrombosis, Rivaroxaban | 01/22 | 12/22 | | |
| Recruiting | N/A | 1200 | RoW | Rivaroxaban | Samsung Medical Center, Bayer | Atrial Fibrillation, Rivaroxaban, Elderly, Renal Insufficiency | 02/22 | 08/22 | | |
PRO-PAS, NCT06239415: PAtients With Symptomatic Peripheral Artery Disease on Rivaroxaban-acetylsalicylic Acid Combination Therapy |
|
|
| Recruiting | N/A | 250 | Europe | observation | Istituti Clinici Scientifici Maugeri SpA, Società Italiana Cardiologia Ospedalità Accreditata (SICOA) | Peripheral Atherosclerotic Disease | 03/24 | 03/24 | | |
NCT05669313: The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM |
|
|
| Completed | N/A | 15 | Europe | Rivaroxaban 15 MG | Thomas Kander | Trauma, Hypothermia, Acidosis, Bleeding | 11/22 | 11/22 | | |
| Recruiting | N/A | 100 | Europe | Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban, INTERMITTENT GROUP, Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban, CHRONIC GROUP | University of Roma La Sapienza | Ischemic Heart Disease, Atrial Fibrillation | 11/22 | 11/23 | | |
ELAN, NCT03148457: Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial |
|
|
| Completed | N/A | 2013 | Europe, Japan, RoW | Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®), Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®) | Insel Gruppe AG, University Hospital Bern | Ischaemic Stroke | 12/22 | 05/23 | | |
ChiCTR2000033144: A prospective cohort study of the correlation between inflammation indicators and the clinical efficacy and safety of rivaroxaban |
|
|
| Not yet recruiting | N/A | 112 | | N/A ;N/A | The Fifth People's Hospital of Shanghai; The Fifth People's Hospital of Shanghai, Scientific Research Project funded by Shanghai Municipal Health Commission | Thromboembolic disease | | | | |
UniXa, NCT04539301: Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels |
|
|
| Recruiting | N/A | 2100 | Europe | Estimated anticoagulant level (conversion factor x anti-Xa activity) | Nantes University Hospital | Anticoagulation, Venous Thromboembolism, Atrial Fibrillation | 05/24 | 05/24 | | |
NCT06371170: Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population |
|
|
| Recruiting | N/A | 20 | Europe | Rivaroxaban, Xarelto | Azienda Ospedaliero, Universitaria Ospedali Riuniti | Intracardiac Thrombus | 01/25 | 01/27 | | |
NCT04486859: Postoperative Thrombosis Prevention in Patients With CD |
|
|
| Recruiting | N/A | 206 | RoW | LMWH/Rivaroxaban, IPC | Huashan Hospital, Peking Union Medical College Hospital, West China Hospital | Cushing Disease, DVT, Pulmonary Embolism | 01/23 | 07/23 | | |
OSCAR SWE, NCT05150938: A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE) |
|
|
| Completed | N/A | 5737 | Europe | Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), vitamin K antagonist (VKA), other NOACs | Bayer, Janssen Research & Development, LLC | Treatment of Venous Thromboembolism in Cancer Patients | 02/23 | 02/23 | | |
NCT05546957: Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants |
|
|
| Completed | N/A | 60 | Europe | Aspirin, rivaroxaban low dose, rivaroxaban high dose | Regeneron Pharmaceuticals | Healthy Volunteer | 04/23 | 04/23 | | |
| Active, not recruiting | N/A | 1 | Europe | Apixaban, Rivaroxaban, Edoxaban, Dabigatran, VKA, LMWH | Pfizer | Neoplasms, Embolism | 12/24 | 12/24 | | |
XATOC, NCT04401761: A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs |
|
|
| Completed | N/A | 3189 | Europe, RoW | Rivaroxaban (BAY59-7939, Xarelto), Xarelto, Acetylsalicylic acid, Aspirin | Bayer | Coronary Artery Disease, Peripheral Artery Disease | 06/23 | 09/23 | | |
ChiCTR2000038963: Exploratory Study of Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants Rivaroxaban in Patients with Left Ventricular Thrombus |
|
|
| Not yet recruiting | N/A | 60 | | Rivaroxaban | Fuwai Hospital, Chinese Academy of Medical Sciences & Pecking Union Medical College; Fuwai Hospital, Chinese Academy of Medical Sciences & Pecking Union Medical College, Self-funded | Left Ventricular Thrombus | | | | |
ChiCTR2200067149: Effect of Qitao Huayu Prescription on DVT after TKA and mechanism of inflammatory regulation |
|
|
| Recruiting | N/A | 100 | | Rivaroxaban + Qitao Huayu Prescription ;Rivaroxaban | Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai Health and Family Planning Commission | Deep vein thrombosis | | | | |
NCT04753372: Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk |
|
|
| Completed | N/A | 645 | Europe | Rivaroxaban 2.5 MG [Xarelto], acetylsalicylic acid (ASA) | Maatschap Cardiologie Zwolle, Diagram B.V. | Coronary Artery Disease (CAD), Peripheral Arterial Disease (PAD) | 09/23 | 09/23 | | |
REATTAIN, NCT04249401: Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) |
|
|
| Completed | N/A | 134897 | Europe | Rivaroxaban (Xarelto), Apixaban, Dabigatran, Warfarin | Bayer, Janssen, LP | Atrial Fibrillation | 09/23 | 09/23 | | |
NCT04297150: Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation.. |
|
|
| Active, not recruiting | N/A | 700 | Europe | Apixaban, Eliquis, Edoxaban, Lixiana, Rivaroxaban, Xarelto, Dabigatran, Pradaxa | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Atrial Fibrillation | 09/23 | 09/23 | | |
NCT06196918: Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients |
|
|
| Recruiting | N/A | 320 | RoW | Rivaroxaban 10 MG, Jiangsu Zhongbang pharmaceutical CO., LTD; Serial numbers: H20203733, Placebo, Jiangsu Zhongbang pharmaceutical CO., LTD | Nanfang Hospital, Southern Medical University | Glioma, Malignant | 08/24 | 02/25 | | |
| Active, not recruiting | N/A | 60 | Europe | Coronary computed tomography angiography, Invasive coronary angiography, Transthoracic echocardiography, Cardiac MRI scan, Antiplatelet Drug (Aspirin or Statin), Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin), Guideline directed heart failure therapy, Statins (Cardiovascular Agents) | University of Edinburgh, Chief Scientist Office of the Scottish Government | Myocardial Infarction Type 2 | 06/24 | 06/24 | | |
STAR-D, NCT05093504: Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban |
|
|
| Terminated | N/A | 9 | US | Sham comparator, DrugSorb-ATR system, Sorbent hemoperfusion system | CytoSorbents, Inc | Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative | 01/24 | 01/24 | | |
NCT05750758: Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty |
|
|
| Completed | N/A | 140 | RoW | rivaroxaban | Henan Institute of Cardiovascular Epidemiology | Acute Coronary Syndrome | 08/23 | 12/23 | | |
NCT05744804: Efficacy and Safety of Low Dose Rivaroxaban in Patients With Anterior Myocardial Infarction |
|
|
| Not yet recruiting | N/A | 150 | RoW | -group of patients(75 patients) will receive low dose rivaroxaban myocardial infarction plus (acetylsalicylic acid 75 mg and clopidogrel 75 mg, (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally only) | Sohag University | Patient With Anterior Myocardial Infarction | 12/23 | 12/23 | | |
NCT04477837: Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants |
|
|
| Active, not recruiting | N/A | 150 | Europe | Apixaban 5 MG, Eliquis, Rivaroxaban 20 MG, Xarelto, Edoxaban 60 MG, Lixiana, Dabigatran 150 Mg Oral Capsule, Pradaxa | Cardioangiologisches Centrum Bethanien | Heavy Menstrual Bleeding | 05/24 | 06/24 | | |
TROMBIXDZ, NCT06184204: Observational Study:Safety,Efficacy and Quality of Life of Patients With Atrial Fibrillation, Treated With Trombix® |
|
|
| Active, not recruiting | N/A | 400 | RoW | Trombix® (Rivaroxaban), Trombix® | Beker Laboratories | Atrial Fibrillation | 12/24 | 04/25 | | |
R-DISSOLVE, NCT04970381: An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus |
|
|
| Recruiting | N/A | 60 | RoW | Rivaroxaban | China National Center for Cardiovascular Diseases | Ventricular Mural Thrombosis | 12/23 | 12/23 | | |
NCT03005444: Anticoagulation for Advanced Cirrhotic Patients After TIPS |
|
|
| Recruiting | N/A | 254 | RoW | Rivaroxaban, Nadroparin or Enoxaparin | Air Force Military Medical University, China | Liver Cirrhosis | 12/23 | 12/24 | | |
NCT03772457: Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban |
|
|
| Recruiting | N/A | 400 | RoW | Rivaroxaban | Second Affiliated Hospital, School of Medicine, Zhejiang University, Bayer, Taizhou Hospital, Zhuji People's hospital, Shaoxing People's Hospital, Jinhua Central Hospital, HaiyanPeople's hospital, Wenzhou Central Hospital, The Central Hospital of Lishui City, Dongyang People's Hospital, Rui'an People's hospital | Cerebrovascular Stroke, Intracranial Hemorrhages, Anticoagulant, Matrix Metalloproteinases | 12/23 | 12/24 | | |
ChiCTR2100046725: The efficacy and safety of Warfarin and Rivaroxaban to prevent re‐occlusion for Budd-Chiari syndrome with membranous obstruction after percutanouse balloon angioplasty |
|
|
| Recruiting | N/A | 80 | | oral take Warfarin ;oral take rivaroxaban | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, None | Budd-Chiari syndrome | | | | |
ChiCTR2300074651: Efficacy and safety of rivaroxaban in pediatric venous thromboembolic diseases |
|
|
| Recruiting | N/A | 504 | | N/A ;N/A | College of Pharmacy, Chongqing Medical University; College of Pharmacy, Chongqing Medical University, National Natural Science Foundation of China | Venous thromboembolic disease in children | | | | |
| Not yet recruiting | N/A | 30 | | None | Beijing You 'an Hospital, Capital Medical University; Beijing You 'an Hospital, Capital Medical University, Open project of Beijing Institute of Hepatology | Cirrhosis | | | | |
NCT03642509: Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation |
|
|
| Recruiting | N/A | 750 | Europe | Left atrial appendage occlusion, Left atrial appendage closure, NOAC, Edoxaban, Apixaban, Rivaroxaban, Dabigatran | University of Aarhus, Aarhus University Hospital, Aalborg University Hospital, Odense University Hospital, Sahlgrenska University Hospital, Sweden, Karolinska University Hospital, Haukeland University Hospital, Helsinki University Central Hospital, Gødstrup Hospital, Lund University Hospital, Oslo University Hospital, Trondheim University Hospital, Rigshospitalet, Denmark, Jena University Hospital | Atrial Fibrillation, Stroke | 01/26 | 10/30 | | |
NCT06362343: The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics |
|
|
| Recruiting | N/A | 300 | RoW | Rivaroxaban | Peking Union Medical College Hospital, Ruijin Hospital, Xiangya Hospital of Central South University, China-Japan Friendship Hospital | Pulmonary Embolism | 10/26 | 01/27 | | |
| Recruiting | N/A | 400 | RoW | Rivaroxaban | Seoul National University Hospital, Samjin Pharmaceutical Co., Ltd., Medtronic Korea Co., Ltd. | Atrial Fibrillation | 12/30 | 12/30 | | |
NCT06278051: An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism |
|
|
| Recruiting | N/A | 100 | Japan | Rivaroxaban granules for oral suspension, Xarelto, BAY59-7939, Warfarin | Bayer, Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical Research & Development L.L.C.) | Venous Thromboembolism | 12/24 | 12/24 | | |
XARIN, NCT03887780: A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF) |
|
|
| Active, not recruiting | N/A | 504 | RoW | Rivaroxaban (Xarelto,Bay 59-7939) | Bayer, Janssen Research & Development, LLC | Non-valvular Atrial Fibrillation (NVAF) | 12/23 | 08/24 | | |
eVTE, NCT06232551: Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism |
|
|
| Not yet recruiting | N/A | 152000 | US | EHR (electronic health record) alert, No EHR (electronic health record) alert | Scott C. Woller, MD, Janssen Pharmaceuticals | Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Deep Vein Thrombosis, Hospitalism | 01/25 | 09/25 | | |
NCT04298567: Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD) |
|
|
| Completed | N/A | 300 | RoW | Rivaroxaban (Xarelto,Bay 59-7939), Acetylsalicylic acid(ASA) | Bayer | Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD), Symptomatic Peripheral Artery Disease (Symptomatic PAD) | 03/24 | 06/24 | | |
SIFNOS, NCT05838664: A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France |
|
|
| Completed | N/A | 3691397 | Europe | No OAC, VKA, apixaban, rivaroxaban, dabigatran | Pfizer | Atrial Fibrillation | 03/24 | 03/24 | | |
ChiCTR2200058611: Evaluation of the efficacy and safety of rivaroxaban in patients with valvular atrial fibrillation: A randomized controlled clinical trial protocol |
|
|
| Not yet recruiting | N/A | 70 | | rivaroxaban ;warfarin or other treatment | The Second Hospital of Hebei Medical University; The Second Hospital of Hebei Medical University, Key scientific and technological research plan (grant no. 20211208) | valvular atrial fibrillation | | | | |
OPTIMAS, NCT03759938: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial |
|
|
| Active, not recruiting | N/A | 3648 | Europe | Direct oral anticoagulant (DOAC), dabigatran, apixaban, edoxaban, rivaroxaban | University College, London | Stroke, Acute, Atrial Fibrillation | 05/24 | 10/24 | | |
NCT04694248: Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting |
|
|
| Recruiting | N/A | 172 | RoW | Rivaroxaban, Anticoagulant, Aspirin, Antiplatelet | First Affiliated Hospital of Zhejiang University, Zhejiang University, Ningbo No.2 Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City, Taizhou Enze Hospital, Taizhou First People's Hospital, Boston Scientific Corporation | Deep Vein Thrombosis, Iliac Vein Thrombosis, Iliac Vein Obstruction, Iliac Vein Stenosis, Iliac Vein Compression Syndrome | 12/25 | 06/26 | | |
NCT06193863: An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure |
|
|
| Not yet recruiting | N/A | 50 | Japan | Rivaroxaban (Xarelto, BAY59-7939) | Bayer, Janssen Research & Development, LLC | Prevention of Venous Thromboembolism, Congenital Heart Disease, Fontan Procedure, Children | 06/26 | 12/26 | | |
| Recruiting | N/A | 1600 | Europe | dabigatran, rivaroxaban, apixaban or edoxaban, Pradaxa, Xarelto, Eliquis or Lixiana | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Daiichi Sankyo | Atrial Fibrillation, Recurrent Venous Thromboembolism | 08/24 | 08/24 | | |
HELIOS-AF, NCT05038228: High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France |
|
|
| Active, not recruiting | N/A | 1 | Europe | Apixaban, Rivaroxaban, Dabigatran, Vitamin K antagonist (VKA) | Pfizer | Atrial Fibrillation | 08/24 | 08/24 | | |
ChiCTR2200062662: Impact of combination of rivaroxaban with amiodarone on bleeding in atrial fibrillation patients with renal dysfunction |
|
|
| Not yet recruiting | N/A | 784 | | None ;None ;None ;None | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Key Clinical Specialty Research Program Shanghai | atrial fibrillation | | | | |
NCT02921022: Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma |
|
|
| Active, not recruiting | N/A | 110 | US | Gemcitabine, Nab-paclitaxel, PEGPH20 | Memorial Sloan Kettering Cancer Center, Halozyme Therapeutics, Miami Cancer Institute | Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma | 10/25 | 10/25 | | |
ACTonLVT, NCT05892042: Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction |
|
|
| Recruiting | N/A | 320 | RoW | Rivaroxaban 15 MG [Xarelto], Xarelto | Jilin University | ST-segment Elevation Myocardial Infarction (STEMI), Left Ventricular Thrombus | 10/24 | 04/25 | | |
ChiCTR2200062948: Clinical Study of Buyang Huanwu Decoction Plus Modified Prescription Combined with Anticoagulant Early Intervention on the Prevention of Post Thrombosis Syndrome in Lower Extremity Deep Vein |
|
|
| Not yet recruiting | N/A | 80 | | Buyang Huanwu Decoction ;Oral Rivaroxaban Tablets | Wangjing Hospital of CACMS; Wangjing Hospital of CACMS, Hospital appropriation | post-thrombotic syndrome | | | | |
| Recruiting | N/A | 300 | Europe, Canada, US, RoW | Direct Oral Anticoagulants, Apixaban, Dabigatran, Edoxaban, Rivaroxaban | University of Malta, Università degli Studi dell'Insubria | Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis, Renal Vein Thrombosis, Retinal Vein Thrombosis | 12/24 | 12/24 | | |
| Recruiting | N/A | 400 | Europe | Monitoring | Groupe Hospitalier Pitie-Salpetriere | Anticoagulants and Thrombotic Disorders | 12/24 | 12/24 | | |
ChiCTR2200063028: Randomized controlled study of anticoagulant drugs for portal vein thrombosis in cirrhotic patients with gastroesophageal varices after endoscopic treatment |
|
|
| Not yet recruiting | N/A | 42 | | Rivaroxaban ;Nadroparin calcium | Beijing You'an Hospital, Capital Medical University; Beijing You'an Hospital, Capital Medical University, Capital Health Development Scientific Research Project (2022) | Cirrhotic esophageal varices with portal vein thrombosis | | | | |
ChiCTR2300073445: Study on different anticoagulant course of isolated intermuscular venous thrombosis of calf after major orthopaedic surgery |
|
|
| Not yet recruiting | N/A | 200 | | After diagnosis of MCVT, oral rivaroxaban 10 mg/time, QD until discharge; after discharge, oral rivaroxaban tablets 10 mg/time, QD, anticoagulant treatment until 6 weeks ;After diagnosis of MCVT, oral rivaroxaban 10 mg/time, QD until discharge; after discharge, oral rivaroxaban tablets 10 mg/time, QD, anticoagulant treatment until 3 months | The Second Affiliated Hospital of Soochow University; The Second Affiliated Hospital of Soochow University, self-funded | Intermuscular vein thrombosis | | | | |
| Recruiting | N/A | 500 | Europe | Rivaroxaban, Dabigatran, Apixaban, Edoxaban | Stéphane Zuily, International Society on Thrombosis and Haemostasis | Antiphospholipid Syndrome, Thrombosis, Anticoagulants Causing Adverse Effects in Therapeutic Use | 04/30 | 04/30 | | |
| Enrolling by invitation | N/A | 100 | RoW | AngioJet device, Zalente, anticoagulation alone, rivaroxaban | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Boston Scientific Corporation | Acute Deep Venous Thrombosis of Femoral Vein (Disorder) | 06/25 | 06/25 | | |
| Recruiting | N/A | 300 | Europe, US | ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. | Inari Medical | Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome | 06/25 | 10/25 | | |
